1116229-11-8

Basic information

• Product Name: 1-(4-(3-Methoxy-4-nitrophenyl)piperazin-1-yl)ethanone
• Synonyms: 1-(4-(3-Methoxy-4-nitrophenyl)piperazin-1-yl)ethanone;1-acetyl-4-[3-(methyloxy)-4-nitrophenyl]piperazine;1-[4-(3-methoxy-4-nitrophenyl)piperazin-1-yl]ethan-1-one
• CAS NO: 1116229-11-8
• Molecular Formula: C₁₃H₁₇N₃O₄
• Molecular Weight: 279.29178
• EINECS: -0
• Mol File: 1116229-11-8.mol
• Article Data: 25

Chemical Properties

• Boiling Point: 510.9±50.0 °C(Predicted)
• Appearance: /
• Density: 1.270±0.06 g/cm3(Predicted)
• PKA: 1.19±0.20(Predicted)
• CAS DataBase Reference: 1-(4-(3-Methoxy-4-nitrophenyl)piperazin-1-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-(3-Methoxy-4-nitrophenyl)piperazin-1-yl)ethanone(1116229-11-8)
• EPA Substance Registry System: 1-(4-(3-Methoxy-4-nitrophenyl)piperazin-1-yl)ethanone(1116229-11-8)

Safety Data

• Hazardous Substances Data: 1116229-11-8(Hazardous Substances Data)

Usage

General Description

1-(4-(3-Methoxy-4-nitrophenyl)piperazin-1-yl)ethanone, also known as 3-Methoxy-4-nitro-N-(4-(piperazin-1-yl)phenyl)benzamide, is a chemical compound with the molecular formula C14H18N4O4. 1-(4-(3-Methoxy-4-nitrophenyl)piperazin-1-yl)ethanone belongs to the class of organic compounds known as N-arylpiperazines. It is a derivative of piperazine and contains a piperazin-1-yl group attached to an ethanone moiety. 1-(4-(3-Methoxy-4-nitrophenyl)piperazin-1-yl)ethanone has potential pharmacological and biological activities and is often used in the development of pharmaceutical drugs and research studies.

Upstream product

• 108-24-7 acetic anhydride 
• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 75-36-5 acetyl chloride 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 1017782-79-4 tert-butyl 4-(3-methoxy-4-nitrophenyl)piperazine-1-carboxylate 
• 446-36-6 5-fluoro-2-nitrophenol 
• 13889-98-0 N-acetylpiperidine 

Downstream Products

• 1021426-42-5 1-(4-{4-amino-3-methoxyphenyl}piperazine-1-yl)ethan-1-one 
• 1453198-88-3 N-[4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl]acetamide 
• 1453198-89-4 1-[4-[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-3-methoxyphenyl]piperazin-1-yl]ethanone 
• 1625677-48-6 N-(3-(2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide 

Relevant articles and documents

TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF

Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g, X11, X22, R11, R22, R33, R44, R55, R66, R77, R88, m, n) are as described herein. Compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions of either of the foregoing, and combinations of any of the foregoing can be used to treat tyrosine kinase non- receptor 1 (TNK1)-mediated diseases, disorders and conditions.

Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibition agents

Anaplastic lymphoma kinase (ALK) targeted therapies have demonstrated remarkable efficacy in ALK-positive lung adenocarcinomas. Here we synthesized and evaluated sixteen new 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibitors. The optimal compound 9e exhibited excellent antiproliferative activity against non-small cell lung cancer NCI-H2228 cells, which is better than that of Brigatinib and similar to Ceritinib. Mechanism study revealed that the optimal compound 9e decreased the mitochondrial membrane potential and arrested NCI-H2228 cells in the G0/G1 phase, finally resulting in cellular apoptosis. It is interesting that 9e could effectively inhibit the migration of NCI-H2228 cells and may be a promising leading compound for chemotherapy of metastatic cancer.

Discovery and structure ? activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors

Internal tandem duplications of FLT3 (FLT3-ITD) occur in approximately 25% of all acute myeloid leukemia (AML) cases and confer a poor prognosis. Optimization of the screening hit 1 from our in-house compound library led to the discovery of a series of pyrazolo[1,5-a]pyrimidine derivatives as potent and selective FLT3-ITD inhibitors. Compounds 17 and 19 displayed potent FLT3-ITD activities both with IC50 values of 0.4 nM and excellent antiproliferative activities against AML cell lines. Especially, compounds 17 and 19 inhibited the quizartinib resistance- conferring mutations, FLT3D835Y, both with IC50 values of 0.3 nM. Moreover, western blot analysis indicated that compounds 17 and 19 potently inhibited the phosphorylation of FLT3 and attenuated downstream signaling in AML cells. These results indicated that pyrazolo[1,5-a]pyrimidine derivatives could be promising FLT3-ITD inhibitors for the treatment AML.